News
Filter by year:
-
Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease
-
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
-
M Ventures co-leads Cyllene Therapeutics' €33 million Series C raise alongside GordonMD.
-
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody
-
Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers
-
Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer
-
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
-
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
-
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
-
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
-
Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform
-
Repronovo Appoints Mark Altmeyer as Chairman of the Board
-
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
-
Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)
-
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
-
Celebrate women in science with Optimum
-
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
-
Concerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient Discovery
-
UNISERS Ships First Fully-Automated Fab Tool and Strengthens Leadership to Scale In-Fab Deployment
-
SEEQC and Allegro Merger Corp. Enter Into Merger Agreement
-
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
-
Altoida and Mindspan Announce Research Collaboration to Use AI/AR-Powered Digital Cognitive Assessment to Personalize Cognitive Care
-
Iktos named Top BioTech and Life Sciences Companies of 2025
-
Iktos Enters Strategic €1B+ Multi-Target AI Partnership with Servier to Advance Drug Discovery in Oncology and Neurology
-
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration
-
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
-
M Ventures: Pharma CVC and biotech innovation in 2026
-
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
